Rufinamide
Active ingredient: Rufinamide
In short: Rufinamide is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in pediatric patients 1 year of age and older and in adults.
What is Rufinamide used for?
Rufinamide is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in pediatric patients 1 year of age and older and in adults.
Rufinamide dosage
Pediatric Patients (1 Year to Less than 17 Years): The recommended starting daily dose of rufinamide in pediatric patients with Lennox-Gastaut Syndrome is approximately 10 mg/kg administered in two equally divided doses. The dose should be increased by approximately 10 mg/kg increments every other day until a maximum daily dose of 45 mg/kg, not to exceed 3200 mg, administered in two equally divided doses, is reached. It is not known whether doses lower than the target doses are effective.
Adults (17 Years and Older): The recommended starting daily dose of rufinamide in adults with Lennox-Gastaut Syndrome is 400 to 800 mg per day administered in two equally divided doses. The dose should be increased by 400 to 800 mg every other day until a maximum daily dose of 3200 mg, administered in two equally divided doses, is reached. It is not known whether doses lower than 3200 mg are effective.
Administer rufinamide with food.
Rufinamide oral suspension should be shaken well before every administration.
Hemodialysis may reduce exposure to a limited (about 30%) extent. Accordingly, adjusting the rufinamide dose during the dialysis process should be considered
.
Use of rufinamide in patients with hepatic impairment has not been studied. Therefore, use in patients with severe hepatic impairment is not recommended. Caution should be exercised in treating patients with mild to moderate hepatic impairment
.
Patients taking valproate should begin rufinamide at a dose lower than 10 mg/kg per day in pediatric patients or 400 mg per day adults
.
How to take Rufinamide — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).
Administration Information:
Advise patients to take rufinamide with food
.
Advise patients who are prescribed the oral suspension to shake it vigorously before administration
.
Suicidal Thinking and Behavior: Inform patients, their caregivers, and families that antiepileptic drugs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers
.
Central Nervous System Reactions: Inform patients about the potential for somnolence or dizziness and advise them not to drive or operate machinery until they have gained sufficient experience on rufinamide to gauge whether it adversely affects their mental and/or motor performance
.
Multi-Organ Hypersensitivity Reactions: Advise patients to notify their physician if they experience a rash associated with fever
. …
Warnings & precautions
Do not take this medicine if: Rufinamide is contraindicated in patients with Familial Short QT syndrome
.
Antiepileptic drugs (AEDs), including rufinamide, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.
Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide.
The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.
The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. …
Rufinamide side effects
The following serious adverse reactions are described below and elsewhere in the labeling:
Suicidal Behavior and Ideation
Central Nervous System Reactions
QT Shortening
Multi-Organ Hypersensitivity/ Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
Leukopenia
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adverse Reactions in Adult and Pediatric Patients Ages 3 to 17 Years of Age: In the pooled, double-blind, adjunctive therapy studies in adult and pediatric patients ages 3 to 17 years of age, the most common (≥10%) adverse reactions in rufinamide-treated patients, in all doses studied (200 to 3200 mg per day) with a higher frequency than in patients on placebo were: headache, dizziness, fatigue, somnolence, and nausea.
Table 2 lists adverse reactions that occurred in at least 3% of pediatric patients (ages 3 to less than 17 years) with epilepsy treated with rufinamide in controlled adjunctive studies and were numerically more common in patients treated with rufinamide than in patients on placebo.
At the target dose of 45 mg/kg per day for adjunctive therapy in pediatric patients (ages 3 to less than 17 years), the most common (≥3%) adverse reactions with an incidence greater than in placebo for rufinamide were somnolence, vomiting, and headache. …
Drug interactions
Population pharmacokinetic analysis of average concentration at steady state of carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, and valproate showed that typical rufinamide C
avss levels had little effect on the pharmacokinetics of other AEDs. Any effects, when they occur, have been more marked in the pediatric population.
Table 6 summarizes the drug-drug interactions of rufinamide with other AEDs.
AED Co-administered | Influence of Rufinamide on AED concentration
Predictions are based on rufinamide concentrations at the maximum recommended dose of rufinamide. | Influence of AED on Rufinamide Concentration
Carbamazepine | Decrease by 7 to 13%
Maximum changes predicted to be in pediatric patients and in adult patients who achieve significantly higher levels of rufinamide, as the effect of rufinamide on these AEDs is concentration-dependent. | Decrease by 19 to 26%
Dependent on dose of carbamazepine
Lamotrigine | Decrease by 7 to 13% | No Effect
Phenobarbital | Increase by 8 to 13% | Decrease by 25 to 46%
Larger effects in pediatric patients at high doses/concentrations of AEDs.,
Phenobarbital, primidone and phenytoin were treated as a single covariate (phenobarbital-type inducers) to examine the effect of these agents on rufinamide clearance. …
About this medicine
Rufinamide is a triazole derivative structurally unrelated to currently marketed antiepileptic drugs (AEDs). Rufinamide has the chemical name 1-[(2,6-difluorophenyl)methyl]-1
H-1,2,3-triazole-4 carboxamide. It has an empirical formula of C
10H
8F
2N
4O and a molecular weight of 238.20. The drug substance is a white crystalline powder. Rufinamide is practically insoluble in water, slightly soluble in tetrahydrofuran and in methanol, and very slightly soluble in ethanol and in acetonitrile.
Rufinamide Oral Suspension is available for oral administration as a liquid containing rufinamide, USP at a concentration of 40 mg/mL. Inactive ingredients include: anhydrous citric acid, hydroxyethyl cellulose, methylparaben, microcrystalline cellulose and carboxymethylcellulose sodium, poloxamer, potassium sorbate, propylene glycol, propylparaben, purified water, simethicone emulsion, sodium hydroxide, sorbitol solution and orange flavoring.
How it works: The precise mechanism(s) by which rufinamide exerts its antiepileptic effect is unknown. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 1a0b80de-754d-4e60-b5a9-b6daa323bf58. Read the full official label on DailyMed.
Related medicines
Gabapentin Lamotrigine Pregabalin Topiramate Levetiracetam Oxcarbazepine Carbamazepine Ciclopirox